Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Annals of Oncology|2019Cited by 475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng‐Hua Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Journal of Clinical Oncology|2021Cited by 350
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Sheng Yao et al.|Signal Transduction and Targeted Therapy|2021Cited by 94
Zebrafish B Cell Development without a Pre–B Cell Stage, Revealed by CD79 Fluorescence Reporter TransgenesXingjun Liu, Richard R. Hardy, Yuesheng Li et al.|The Journal of Immunology|2017Cited by 54
Astragaloside IV ameliorates diabetic nephropathy in <i>db/db</i> mice by inhibiting NLRP3 inflammasome‑mediated inflammationHui Feng, Ximing Liu|International Journal of Molecular Medicine|2021Cited by 51